Antares Pharma Inc (NASDAQ:ATRS) Adds Experience To The Management Team With New Appointment


Dallas, Texas 07/15/2015 (Financialstrend) – Peter J. Graham is to join Antares Pharma Inc (NASDAQ:ATRS) as its Senior Vice President, General Counsel, Chief Compliance Officer and corporate officer. He joins the company with vast experience in the fields of legal health care, contract negotiations as well as experience in mergers and acquisitions.

Graham’s Experience

Graham is to spearhead Antares Pharma Inc (NASDAQ:ATRS) efforts in remaining compliant with the SEC regulations while carrying out his other general corporate responsibilities. He will be reporting to the company’s president and chief executive officer Eammon P Hobbs. Until his appointment, Graham worked at Death Systems as the company’s Executive Vice president, general counsel, and Chief compliance officer.

Graham has also worked at ACIST Medical Systems, a company that specializes in diagnostic and therapeutic medical devices for radiology and cardiology.  He is accredited for efficiently managing the corporate accounts and global legal affairs teams that allowed ACIST Medical Systems to expand its corporate contract business

Graham’s legal expertise, as well as proven global strategy management leadership in private and publicly traded companies, should be a great addition to Antares Pharma Inc (NASDAQ:ATRS). He takes over from Jennifer Evans Stacey, who is leaving the company. Stacy bows out after successfully leading the company to the settlement of the Medac litigation having also played a pivotal role in the integration of the company’s first in-house sales force.

Merger and Acquisition Experience

Antares Pharma Inc (NASDAQ:ATRS) should bank on Grahams experience on merger and acquisitions having worked on the AngioDynamics, Inc. (NASDAQ:ANGO) Board of Directors between 2006 and 2007. During this period, he was instrumental in the eventual acquisition of Rita Medical Systems for $220 million having also overseen a $75 million follow-on offering

The stock is currently rate as a ‘Hold’ by analysts at Zacks as other investment firms maintain an average of a buy rating.